Cristina Gonzalez-Robles

Dr. Cristina Gonzalez-Robles

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in Movement Disorders
Verified
Journal Article
Open access
CGCristina Gonzalez-Robles
Cristina Gonzalez-Robles
MBMichèle Bartlett
Michèle Bartlett
MBMatthew Burnell
Matthew Burnell
CCCaroline S. Clarke
Caroline S. Clarke
SHShlomi Haar
Shlomi Haar
TCthe EJS ACT‐PD Consortium
the EJS ACT‐PD Consortium
Background: Clinical trials of disease‐modifying therapies in PD require valid and responsive primary outcome measures that are relevant to patients.Objectives: The objective is to select a patient‐centered primary outcome measure for disease‐modification trials over three or more years.Methods: Experts in Parkinson's disease (PD), statistics, and health economics and patient and public involvement and engagement (PPIE) representatives reviewed and discussed potential outcome measures. A larger PPIE group provided input on their key considerations for such an endpoint. Feasibility, clinimetric properties, and relevance to patients were assessed and synthesized.Results: Although initial considerations favored the Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) Part III in Off, feasibility, PPIE input, and clinimetric properties supported the MDS‐UPDRS Part II. However, PPIE input also highlighted the importance of nonmotor symptoms, especially in the longer term, leading to the selection of the MDS‐UPDRS Parts I + II sum score.Conclusions: The MDS‐UPDRS Parts I + II sum score was chosen as the primary outcome for large 3‐year disease‐modification trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

18 April 2025 in Movement Disorders
Verified
Journal Article
Open access
CGCristina Gonzalez-Robles
Cristina Gonzalez-Robles
DADilan Athauda
Dilan Athauda
TBThomas R. Barber
Thomas R. Barber
RBRoger A. Barker
Roger A. Barker
DDDavid T. Dexter
David T. Dexter
TCthe EJS ACT‐PD Consortium
the EJS ACT‐PD Consortium
Background: There are currently no disease‐modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT‐PD) initiative will expedite clinical assessment of putative DMTs through a multi‐arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.Objective: The objective of this study was to describe the treatment selection process for the EJS ACT‐PD clinical trial platform.Methods: A Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestions. Compounds were classified into five mechanistic subgroups (mitochondrial, lysosomal, protein, inflammation, “other”). “Go/No‐Go” criteria and a scoring system covering preclinical, pharmacological, and clinical evidence were devised. Experts scored the candidates for quantitative rankings. Dossiers adapted from iLCT documents were produced for the top‐ranked compounds and in turn prioritized by the TSWG. Practical and logistical considerations from the Steering Committee (SC) guided the final decision. Patient and Public Involvement and Engagement representatives provided feedback throughout the process.Results: A total of 293 interventions were identified, 52 of which passed the “Go/No‐Go” criteria and were scored. Dossiers of the 14 top‐ranked compounds were submitted to the SC. Telmisartan, terazosin, and ursodeoxycholic acid were selected as the initial interventions.Conclusions: Drug selection in DMT PD MAMS trials requires consideration of scientific and practical issues. We present a robust system that can inform similar initiatives. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

18 July 2025 in Neurology and Therapy
Verified
Journal Article
Open access
CGCristina Gonzalez-Robles
Cristina Gonzalez-Robles
OBOliver Bandmann
Oliver Bandmann
ASAnthony Schapira
Anthony Schapira
Parkinson disease (PD) is a progressive neurodegenerative condition characterised by tremor, bradykinesia and rigidity, as well as other motor and non-motor symptoms, for which no effective disease-modifying treatments have been discovered. Neuroprotection in PD is limited by its clinical and biological heterogeneity, suboptimal preclinical models, lack of established disease progression biomarkers, complex pathophysiology, the existence of effective symptomatic therapies which hamper the detection of actual disease modification, and trial design. This review discusses the above issues and other important concepts in neuroprotection in PD. The main pathophysiological mechanisms in PD are classified into mitochondrial dysfunction, lysosomal dysfunction, inflammation, protein aggregation/propagation, and "other", and discussed briefly. The most relevant disease-modifying candidates in PD are classified into the aforementioned categories and reviewed. Finally, conclusions and recommendations for future improvements in the field of disease modification in PD are provided.

14 January 2025 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
RPRebecca Petty
Rebecca Petty
VAVeena Agarwal
Veena Agarwal
JAJennifer Allison
Jennifer Allison
SBSandra Bartolomeu-Pires
Sandra Bartolomeu-Pires
MBMichèle Bartlett
Michèle Bartlett
MZMarie-Louise Zeissler
Marie-Louise Zeissler
Background: Timely recruitment and effective retention of participants are challenging for clinical Parkinson's disease (PD) research studies. Not achieving this can affect delivery costs and bias results. Objective: To identify successful recruitment and retention methodologies for clinical research studies in PD. Methods: We conducted a systematic scoping review using a Population, Intervention, Comparator, Outcome and Study design (PICOS) framework to search and screen literature within five databases for published quantitative and mixed methods studies evaluating recruitment and retention strategies of interventional and observational trials in PD. Results: Searches identified 4608 records, of which six papers covering eight studies were included in the review following screening for eligibility. No papers on retention strategies were found that met eligibility criteria. Effective strategies for rapid recruitment included research registries and trial finders (n = 3), digital marketing campaigns (n = 3), site recruitment support (n = 1) and multiple referral sources (n = 1). Recruitment diversity was increased by online campaigns, mandatory 10% minority targets set by funders and supplemental site funding. Conclusions: This scoping review has identified methods that can be used to increase the rate and diversity of recruitment to PD clinical studies. Retention methodologies are under-researched.

3 April 2026 in Brain Stimulation
Verified
Journal Article
Open access
CGCristina Gonzalez-Robles
Cristina Gonzalez-Robles
MMMarco Mancuso
Marco Mancuso
JCJoseph Candelario-McKeown
Joseph Candelario-McKeown
MKMarie T. Krueger
Marie T. Krueger
HAHarith Akram
Harith Akram
PLPatricia Limousin
Patricia Limousin

2 May 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
NMNazgol Motamed-Gorji
Nazgol Motamed-Gorji
YKYoussef Khalil
Youssef Khalil
CGCristina Gonzalez-Robles
Cristina Gonzalez-Robles
SKShamsher Khan
Shamsher Khan
PMPhilippa Mills
Philippa Mills
PGPaola Giunti
Paola Giunti
Ataxia is a common neurological feature of Niemann–Pick disease type C (NPC). In this disease, unesterified cholesterol accumulates in lysosomes of the central nervous system and hepatic cells. Oxidation by reactive oxygen species produces oxysterols that can be metabolised to specific bile acids. These bile acids have been suggested as useful biomarkers to detect NPC. Concentrations of 3β,5α,6β-trihydroxycholanyl glycine (3β,5α,6β-triOH-Gly) and 3β,7β-dihydroxy-5-cholenyl glycine (3β,7β-diOH-Δ5-Gly) were measured in plasma of 184 adults with idiopathic ataxia. All patients were tested with whole genome sequencing containing hereditary ataxia panels, which include NPC1 and NPC2 mutations and other genetic causes of ataxia. Plasma 3β,5α,6β-triOH-Gly above normal (>90 nM) was found in 8 out of 184 patients. One patient was homozygous for the p.(Val1165Met) mutation in the NPC1 gene. The remaining seven included one patient with Friedreich’s ataxia and three patients with autoimmune diseases. Oxidative stress is known to be increased in Friedreich’s ataxia and in autoimmune diseases. Therefore, this subset of patients possibly shares a common mechanism that determines the increase of this bile acid. In a large cohort of adults with ataxia, plasma 3β,5α,6β-triOH-Gly was able to detect the one patient in the cohort with NPC1 disease, but also detected oxidation of cholesterol by ROS in other disorders. Plasma 3β,7β-diOH-Δ5-Gly is not a potential biomarker for NPC1.